Welcome to Clinuvel's dedicated investor website
Welcome to Clinuvel Pharmaceuticals Limited, a biopharmaceutical company with its headquarters in Melbourne and operational offices in San Francisco and Zürich, focused on developing its leading drug candidate afamelanotide (CUV1647) to gain market approval.
As Clinuvel advances its clinical trials, the company seeks to increase awareness of the risks of UV and light exposure, as well as skin and skin disorders. As we grow, more information will become available on these topics, and we aim to share our knowledge online with all of Clinuvel's interested stakeholders.
Latest Announcements
- 14/07/08 Appendix 3X more..
-
01/07/08
- view all announcements
